Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 2080K) PPT slides of all figures Supplemental Material Index Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pascual, V. Articles by Banchereau, J. Search for Related Content PubMed PubMed Citation Articles by Pascual, V. Articles by Banchereau, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Joint Disorders Juvenile Rheumatoid Arthritis Steroids Hazardous Substances DB PREDNISONE Social Bookmarking                      What's this?

¹ Baylor Institute for Immunology Research, Dallas, TX 75204
² Texas Scottish Rite Hospital for Children, Dallas, TX 75219
³ UT Southwestern Medical Center, Dallas, TX 75390

CORRESPONDENCE Virginia Pascual: Virginip{at}Baylorhealth.edu OR Jacques Banchereau: Jacquesb{at}Baylorhealth.edu

Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses 10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, SoJIA PBMCs release large amounts of IL-1ß. We administered recombinant IL-1 receptor antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission was obtained in seven out of nine patients and a partial response was obtained in the other two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that underlies SoJIA and that this cytokine represents a target for therapy in this disease.

V. Pascual and F. Allantaz contributed equally to this work.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Dinarello, C. A. (2009). Interleukin-1β and the Autoinflammatory Diseases. NEJM 360: 2467-2470 [Full Text]  
• Ishikawa, S, Mima, T, Aoki, C, Yoshio-Hoshino, N, Adachi, Y, Imagawa, T, Mori, M, Tomiita, M, Iwata, N, Murata, T, Miyoshi, M, Takei, S, Aihara, Y, Yokota, S, Matsubara, K, Nishimoto, N (2009). Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann Rheum Dis 68: 264-272 [Abstract] [Full Text]  
• Rehani, K., Wang, H., Garcia, C. A., Kinane, D. F., Martin, M. (2009). Toll-Like Receptor-Mediated Production of IL-1Ra Is Negatively Regulated by GSK3 via the MAPK ERK1/2. J. Immunol. 182: 547-553 [Abstract] [Full Text]  
• Sidiropoulos, P I, Goulielmos, G, Voloudakis, G K, Petraki, E, Boumpas, D T (2008). Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis 67: 1382-1389 [Abstract] [Full Text]  
• Li, S. C. (2008). Characteristics of Patients With Systemic-Onset JIA Who Respond to Anti-Interleukin-1 Treatment. AAP Grand Rounds 20: 32-33 [Full Text]  
• Brinster, C., Shevach, E. M. (2008). Costimulatory effects of IL-1 on the expansion/differentiation of CD4+CD25+Foxp3+ and CD4+CD25+Foxp3- T cells. J. Leukoc. Biol. 84: 480-487 [Abstract] [Full Text]  
• Ohlsson, V., Baildam, E., Foster, H., Jandial, S., Pain, C., Strike, H., Ramanan, A. V. (2008). Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47: 555-556 [Full Text]  
• Woo, P. (2008). Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann Rheum Dis 67: 281-282 [Full Text]  
• Lequerre, T, Quartier, P, Rosellini, D, Alaoui, F, De Bandt, M, Mejjad, O, Kone-Paut, I, Michel, M, Dernis, E, Khellaf, M, Limal, N, Job-Deslandre, C, Fautrel, B, Le Loet, X, Sibilia, J, on behalf of the Societe Francophone pour la Rhuma, (2008). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67: 302-308 [Abstract] [Full Text]  
• Wang, X., Jia, S., Geoffrey, R., Alemzadeh, R., Ghosh, S., Hessner, M. J. (2008). Identification of a Molecular Signature in Human Type 1 Diabetes Mellitus Using Serum and Functional Genomics. J. Immunol. 180: 1929-1937 [Abstract] [Full Text]  
• Frosch, M., Roth, J. (2008). New insights in systemic juvenile idiopathic arthritis--from pathophysiology to treatment. Rheumatology (Oxford) 47: 121-125 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Allantaz, F., Chaussabel, D., Stichweh, D., Bennett, L., Allman, W., Mejias, A., Ardura, M., Chung, W., Wise, C., Palucka, K., Ramilo, O., Punaro, M., Banchereau, J., Pascual, V. (2007). Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. JEM 204: 2131-2144 [Abstract] [Full Text]  
• Kaizer, E. C., Glaser, C. L., Chaussabel, D., Banchereau, J., Pascual, V., White, P. C. (2007). Gene Expression in Peripheral Blood Mononuclear Cells from Children with Diabetes. J. Clin. Endocrinol. Metab. 92: 3705-3711 [Abstract] [Full Text]  
• Cimaz, R., Cazalis, M.-A., Reynaud, C., Gerloni, V., Zulian, F., Biggioggero, M., Martini, G., Pontikaki, I., Fantini, F., Mougin, B., Miossec, P. (2007). IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 66: 900-904 [Abstract] [Full Text]  
• Botsios, C., Sfriso, P., Ostuni, P. A., Todesco, S., Punzi, L. (2007). Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46: 1042-1043 [Full Text]  
• Wannamaker, W., Davies, R., Namchuk, M., Pollard, J., Ford, P., Ku, G., Decker, C., Charifson, P., Weber, P., Germann, U. A., Kuida, K., Randle, J. C. R. (2007). (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1beta and IL-18. J. Pharmacol. Exp. Ther. 321: 509-516 [Abstract] [Full Text]  
• Pizarro, T. T., Cominelli, F. (2007). Cloning IL-1 and the Birth of a New Era in Cytokine Biology. J. Immunol. 178: 5411-5412 [Full Text]  
• de Jager, W., Hoppenreijs, E. P A H, Wulffraat, N. M, Wedderburn, L. R, Kuis, W., Prakken, B. J (2007). Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66: 589-598 [Abstract] [Full Text]  
• Teoh, S C B, Sharma, S, Hogan, A, Lee, R, Ramanan, A V, Dick, A D (2007). Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br. J. Ophthalmol. 91: 263-264 [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Carta, S., Tassi, S., Semino, C., Fossati, G., Mascagni, P., Dinarello, C. A., Rubartelli, A. (2006). Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules. Blood 108: 1618-1626 [Abstract] [Full Text]  
• Ozen, S, Hoffman, H M, Frenkel, J, Kastner, D (2006). Familial Mediterranean fever (FMF) and beyond: a new horizon. Fourth International Congress on the Systemic Autoinflammatory Diseases held in Bethesda, USA, 6-10 November 2005. Ann Rheum Dis 65: 961-964 [Abstract] [Full Text]  
• O'Sullivan, B. J., Thomas, H. E., Pai, S., Santamaria, P., Iwakura, Y., Steptoe, R. J., Kay, T. W. H., Thomas, R. (2006). IL-1beta Breaks Tolerance through Expansion of CD25+ Effector T Cells.. J. Immunol. 176: 7278-7287 [Abstract] [Full Text]  
• Dinarello, C. A (2006). Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 83: 447S-455S [Abstract] [Full Text]  
• Portnoy, J., Pan, T., Dinarello, C. A., Shannon, J. M., Westcott, J. Y., Zhang, L., Mason, R. J. (2006). Alveolar type II cells inhibit fibroblast proliferation: role of IL-1{alpha}. Am. J. Physiol. Lung Cell. Mol. Physiol. 290: L307-L316 [Abstract] [Full Text]  
• Hashkes, P. J., Laxer, R. M. (2005). Medical Treatment of Juvenile Idiopathic Arthritis. JAMA 294: 1671-1684 [Abstract] [Full Text]  
• Aarntzen, E H J G, van Riel, P L C M, Barrera, P (2005). Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?. Ann Rheum Dis 64: 1523-1524 [Full Text]  
• Klechevsky, E., Kato, H., Sponaas, A.-M. (2005). Dendritic cells star in Vancouver. JEM 202: 5-10 [Abstract] [Full Text]  
• Dinarello, C. A. (2005). Blocking IL-1 in systemic inflammation. JEM 201: 1355-1359 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS